The Cautionary Tale
The third rebrand: a gray-market tan on the wellness menu
The market has changed costume before. The forum era sold a vial to the self-selected few. The influencer era resold the same vial as a nasal spray with a holiday caption. The supply stack underneath got more professional each time. But the product was always pitched to the same want: a tan without the sun.
The newest costume pitches something bigger.
On wellness-clinic and telehealth menus across the English-speaking internet, Melanotan II now appears among the longevity peptides. It sits beside Epitalon and tesamorelin in benefit lists promising fat loss, metabolic support, immune balance, anti-aging. One clinic’s page describes it as “natural pigmentation, hormone balance and vitality.” The tanning claim is still there. Around it has grown a second skin of medical aspiration.
This is the third rebrand, and it is the most consequential, because it is the first one that borrows a language the molecule never earned.
The claims are laundered receptor science
None of the wellness-menu benefits is invented from nothing. That is what makes them durable.
The melanocortin system is real and does the work the menus allude to. MC3R and MC4R in the hypothalamus regulate hunger and energy expenditure. α-MSH, the hormone Melanotan II imitates, shows anti-inflammatory effects in laboratory studies — it suppresses pro-inflammatory cytokines and supports the pathways that repair UV-damaged DNA. A 2024 review in the Journal of the European Academy of Dermatology and Venereology, by Markus Böhm and colleagues at Münster, Gustave Roussy, Harvard, and Cambridge, lays out the biology carefully.
The laundering happens in the gap between a receptor and a product. A molecule that suppresses inflammation in a dish is not an immune therapy. A pathway that regulates appetite in the brain is not a fat-loss treatment when hit, non-selectively, by an unmeasured vial. The mechanism exists; the medicine does not. What the menu sells is the vocabulary of the first, attached to a product that has none of the second.
Three real melanocortin drugs already exist
Here is the fact that makes the rebrand hollow. The melanocortin system has genuine, approved medicines — and every one of them is the opposite of what the wellness menu offers.
Afamelanotide (Scenesse) is chemically the original Melanotan I. It is an MC1R-selective implant, approved in the EU in 2014 and by the FDA in 2019, for a single rare disease: erythropoietic protoporphyria.
Bremelanotide (Vyleesi) is the deliberate descendant of the Melanotan II self-experiment. The FDA approved it on 21 June 2019 for acquired hypoactive sexual desire disorder in premenopausal women. In its trials, about 25 percent of treated women gained at least 1.2 points on a desire scale, against 17 percent on placebo. Nausea and flushing were common. It works — modestly, specifically, and for one named condition.
Setmelanotide (Imcivree) is an MC4R agonist, more than twenty times more active at the appetite receptor than at the pigment one. The FDA approved it on 27 November 2020 for obesity caused by three ultra-rare genetic defects — POMC, PCSK1, and LEPR deficiency — conditions with around 150 reported cases in the literature, combined. In its trials, 80 percent of patients with POMC or PCSK1 deficiency lost at least ten percent of their body weight in a year.
Three drugs. Each one narrower than the claim it replaced. That is not an accident of history. Selectivity is what got them approved.
What approval actually buys
The useful part is not the label. It is the machinery.
When setmelanotide darkens skin — it did, in 56 percent of patients within the first month — the patient has had a baseline dermatologic examination first, and gets periodic ones after, because the label says so. When two high-risk patients in its program developed early melanomas, the mandated surveillance caught them at stage pT1a, in time for curative excision. When bremelanotide was tested, 684 treated patients were watched for the pigment effects; no cutaneous malignancies were reported, and that absence is a monitored finding, not a hope.
The Böhm review’s bottom line is precisely calibrated. Chronic MC1R activation has not been associated with increased melanoma incidence — but it “does not serve as a complete preventative measure,” and patients on melanocortin drugs should keep limiting UV exposure and keep getting dermatologic surveillance. Even the good news comes with a skin exam attached.
The Böhm review’s bottom line applies to approved drugs with known doses, known purity, and named manufacturers. The wellness-menu vial has none of those. A regulator’s laboratory recently found bottles labelled 30 mg containing between 22 and 54 mg of Melanotan II — the TGA’s own number, on the TGA’s own letterhead. The mole that darkens under those conditions is the diagnostic signal you lose, and there is no dermatologist in the loop, because there is no loop.
Why the costume works
The rebrand works because it is aimed at a different buyer than the spray was. The influencer era sold vanity to the young. The longevity menu sells optimisation to the anxious middle-aged — a market trained by GLP-1s to believe the next breakthrough is a molecule, and trained by podcasts to believe the molecule is available now if you know where to look.
“Hormone balance” is the key phrase. Melanotan II is an analog of a hormone, which is technically true, in the sense that a flood is technically water. The body’s own α-MSH is a local signal, destroyed in minutes. The analog is a body-wide, hours-long activation of five receptor families at once — the pharmacokinetic problem the original developers never solved, and the reason MT-II was abandoned as a drug candidate while its effects were split into the three targeted medicines above.
The wellness menu does not mention any of this. It does not need to. The costume is the argument: listed next to real peptides, in a clinic’s typeface, with an intake form, the product borrows the authority of everything it is not.
What the rebrand proves
Stripped of the vocabulary, the longevity listing is a confession.
It concedes that the honest version of the product — an unapproved, unmeasured, non-selective peptide sold for a tan — has run out of market. The warnings did their work on that pitch. So the market moved to a pitch the warnings have not reached yet, wearing the language of the very discipline — receptor-selective, labelled, monitored — that rejected the molecule decades ago.
A legitimate photoprotective melanocortin drug is still the open question this site keeps pointing at, and it is still labeled as one. What the record shows is that such a drug, if it arrives, will arrive the way the other three did: narrow, selective, tested, and with a skin exam attached. Not on a menu. The three real drugs are the proof of what the target can do. The wellness-menu vial is the proof of what happens to the molecule that couldn’t become one.